While our above results illustrate that coinhibition of the MEK and RTK pathways is crucial for antitumor efficacy in KRAS-mutant NSCLC (Figs. 2g, 3, Supplementary Fig. 4, 5), the precise synergistic mechanism driving this effect remains to be elucidated. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.